Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate Resistant Prostate Cancer.

Zachary Quinn,Benjamin Leiby,Guru Sonpavde,Atish D Choudhury,Christopher Sweeney,David Einstein,Russell Szmulewitz,Oliver Sartor,Karen Knudsen,Eddy Shih-Hsin Yang,Wm Kevin Kelly

Clinical cancer research : an official journal of the American Association for Cancer Research（2022）

引用 3|浏览11

暂无评分

摘要

Combining niraparib with Radium-223 in patients with mCRPC was safe however further studies incorporating biomarkers will better elucidate the role of combinations of PARP inhibitors with DNA damaging and other agents.

查看译文

关键词

prostate cancer,niraparib,castrate-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要